Identification of prognostic factors in canine mammary malignant tumours: a multivariable survival study

BMC Veterinary Research

Augusto J Matos³  Fátima Gärtner²  Irina F Amorim⁴  Joana C Santos¹  Liliana R Martins¹  Jorge R Ribeiro¹  Célia C Lopes⁴  Andreia A Santos³ 

[1] Department of Veterinary Clinics of the Biomedical Sciences Institute of Abel Salazar (ICBAS), University of Porto, Largo Professor Abel Salazar, 2, Porto, 4099-003, Portugal;Institute of Molecular Pathology and Immunology of the University of Porto (IPATIMUP), R Dr. Roberto Frias, s/n, Porto, 4200-465, Portugal;Multidisciplinary Unit for Biomedical Research (UMIB), University of Porto, Largo Professor Abel Salazar, 2, Porto, 4099-003, Portugal;Department of Molecular Pathology and Immunology of the Biomedical Sciences Institute of Abel Salazar (ICBAS), University of Porto, Largo Professor Abel Salazar, 2, Porto, 4099-003, Portugal

关键词: Study;    Survival;    Multivariable;    Tumours, Prognosis;    Mammary;    Canine;   

Others  :  1119637
DOI  :  10.1186/1746-6148-9-1

 received in 2011-10-07, accepted in 2013-01-02,  发布年份 2013

【 摘 要 】

Background

Although several histopathological and clinical features of canine mammary gland tumours have been widely studied from a prognostic standpoint, considerable variations in tumour individual biologic behaviour difficult the definition of accurate prognostic factors. It has been suggested that the malignant behaviour of tumours is the end result of several alterations in cellular physiology that culminate in tumour growth and spread. Accordingly, the aim of this study was to determine, using a multivariable model, the independent prognostic value of several immunohistochemically detected tumour-associated molecules, such as MMP-9 and uPA in stromal cells and Ki-67, TIMP-2 and VEGF in cancer cells.

Results

Eighty-five female dogs affected by spontaneous malignant mammary neoplasias were followed up for a 2-year post-operative period. In univariate analysis, tumour characteristics such as size, mode of growth, regional lymph node metastases, tumour cell MIB-1 LI and MMP-9 and uPA expressions in tumour-adjacent fibroblasts, were associated with both survival and disease-free intervals. Histological type and grade were related with overall survival while VEGF and TIMP-2 were not significantly associated with none of the outcome parameters. In multivariable analysis, only a MIB-1 labelling index higher than 40% and a stromal expression of MMP-9 higher than 50% retained significant relationships with poor overall and disease-free survival.

Conclusions

The results of this study indicate that MMP-9 and Ki-67 are independent prognostic markers of canine malignant mammary tumours. Furthermore, the high stromal expressions of uPA and MMP-9 in aggressive tumours suggest that these molecules are potential therapeutic targets in the post-operative treatment of canine mammary cancer.

【 授权许可】

   
2013 Santos et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Lana SE, Rutteman GR, Withrow SJ: Tumors of the mammary gland. In Small Animal Clinical Oncology. 4th edition. Edited by Withrow SJ, MacEwen EG. St. Louis: Saunders Elsevier; 2007:619-636.
• [2]Sorenmo K: Canine mammary gland tumors. Vet Clin North Am Small Anim Pract 2003, 33:573-596.
• [3]Misdorp W, Else RW, Helmén E, Lipscomb TP: Histological classification of the mammary tumours of the dog and the cat. In World Health Organization International Histological Classification of Tumours of Domestic Animals. 2nd edition. Edited by Shulman FL. Washington DC: Armed Forces Institute of Pathology; 1999:16-29.
• [4]De Las Mulas J, Millán Y, Dios R: A prospective analysis of immunohistochemically determined estrogen receptor α and progesterone receptor expression and host and tumor factors as predictors of disease-free period in mammary tumors of the Dog. Vet Pathol 2005, 42:200-212.
• [5]Ferreira E, Bertagnolli AC, Cavalcanti MF, Schmitt FC, Cassali GD: The relationship between tumour size and expression of prognostic markers in benign and malignant canine mammary tumours. Vet Comp Oncol 2009, 7:230-235.
• [6]Hellmén E, Bergstrom R, Holmberg L, Spangberg IB, Hansson K, Lindgren A: Prognostic factors in canine mammary tumors: a multivariate study of 202 consecutive cases. Vet Pathol 1993, 30:20-27.
• [7]Peña LL, Nieto AI, Pérez-Alenza D, Cuesta P, Castãno M: Immunohistochemical detection of Ki-67 and PCNA in canine mammary tumors: relationship to clinical and pathologic variables. J Vet Diagn Invest 1998, 10:237-246.
• [8]Karayannopoulou M, Kaldrymidou E, Constantinidis TC, Dessiris A: Histological grading and prognosis in dogs with mammary carcinomas: application of a human grading method. J Comp Pathol 2005, 133:1-7.
• [9]Sarli G, Preziosi R, Benazzi C, Castellani G, Marcato PS: Prognostic value of histologic stage and proliferative activity in canine malignant mammary tumours. J Vet Diagn Invest 2002, 14:25-34.
• [10]Pérez-Alenza MD, Peña L, Nieto I, Castaño M: Clinical and pathological prognostic factors in canine mammary tumors. Ann Ist Super Sanita 1997, 33:581-585.
• [11]Nieto A, Peña L, Pérez-Alenza MD, Sánchez MA, Flores JM, Castãno M: Immunohistologic detection of estrogen receptor alpha in canine mammary tumours: clinical and pathologic associations and prognostic significance. Vet Pathol 2000, 37:239-247.
• [12]Walker RA: Immunohistochemical markers as predictive tools for breast cancer. J Clin Pathol 2008, 61:689-696.
• [13]Matos AJF, Lopes CCC, Faustino AMR, Carvalheira JGV, Santos MSA, Rutteman GR, Gärtner MFMR: MIB-1 indices according to clinico-pathological variables in canine mammary tumours: a multivariate study. Anticancer Res 2006, 26:1821-1826.
• [14]Gama A, Alves A, Schmitt F: Identification of molecular phenotypes in canine mammary carcinomas with clinical implications: application of the human classification. Virchows Arch 2008, 453:123-132.
• [15]Sassi F, Benazzi C, Castellani G, Sarli G: Molecular-based tumour subtypes of canine mammary carcinomas assessed by immunohistochemistry. BMC Vet Res 2010, 6:5. BioMed Central Full Text
• [16]Hsu W, Huang H, Liao J, Wong M, Chang S: Increased survival in dogs with malignant mammary tumours overexpressing HER-2 protein and detection of a silent single nucleotide polymorphism in the canine HER-2 gene. The Vet Journal 2009, 180:116-123.
• [17]Egeblad M, Nakasone ES, Werb Z: Tumors as organs: complex tissues that interface with the entire organism. Develop Cell 2010, 18:884-901.
• [18]Brooks SA, Lomax-Browne HJ, Carter TM, Kinch CE, Hall DMS: Molecular interactions in cancer cell metastasis. Acta Histochem 2010, 112:3-25.
• [19]Morris JS, Dobson JM, Bostock DE, O’ Farrell E: Effect of ovariohysterectomy in bitches with mammary neoplasms. Vet Record 1998, 142:656-658.
• [20]Philibert JC, Snyder PW, Glickman N, Knapp DW, Waters DJ: Influence of host factors on survival in dogs with maligant mammary gland tumors. J Vet Intern Med 2003, 17:102-106.
• [21]Yamagi T, Kobayashi T, Takahashi K, Sugiyama M: Prognosis for canine malignant mammary tumors based on TNM classification and histologic classification. J Vet Med Sci 1996, 58:1079-1083.
• [22]Lee C, Kim W, Lim J, Kang M, Kim D, Kweon O: Mutation and overexpression of p53 as a prognostic factor in canine mammary tumors. J Vet Sci 2004, 5:63-69.
• [23]Rayson D, Adjei AA, Suman VJ, Wold LE, Ingle JN: Metaplastic breast cancer: prognosis and response to systemic therapy. Annals of Oncol 1999, 10:413-419.
• [24]Tse JM, Pan PH, Putti TC, Lui PCW, Chaiwun B, Law BKB: Metaplastic carcinoma of the breast: clinicopathological review. J Clin Pathol 2006, 59:1079-1083.
• [25]Löhr CV, Teifke JP, Failing K, Weiss E: Characterization of the proliferation state in canine mammary tumors by the standard AgNOR method with post fixation and immunohistologic detection of Ki-67 and PCNA. Vet Pathol 1997, 34:212-221.
• [26]Gasparini G: Prognostic value of vascular endothelial growth factor in breast cancer. Oncolologist 2000, 5(suppl 1):37-44.
• [27]Mylona E, Alexandrou P, Giannopoulou I, Liapis G, Sofia M, Keramopoulos A, Nakopoulou L: The prognostic value of vascular endothelial growth factors (VEGFs)-A and –B and their receptor, VEGFR-1, in invasive breast carcinoma. Gynecol Oncol 2007, 104:557-563.
• [28]Nieto Y, Woods J, Nawaz F, Baron A, Jones RB, Shpall EJ, Nawaz S: Prognostic analysis of tumour angiogenesis, determined by microvessel density and expression of vascular endothelial growth factor, in high-risk primary breast cancer patients treated with high-dose chemotherapy. Br J Cancer 2007, 97:391-397.
• [29]Millanta F, Silvestri G, Vaselli C, Citi S, Pisani G, Lorenzi D, Poli A: The role of vascular endothelial growth factor and its receptor Flk-1/KDR in promoting tumour angiogenesis in feline and canine mammary carcinomas: a preliminary study of autocrine and paracrine loops. Res Vet Sci 2006, 81:350-357.
• [30]Al-Dissi AN, Haines DM, Singh B, Kidney BA: Immunohistochemical expression of vascular endothelial growth factor receptor-2 in canine simple mammary gland adenocarcinomas. Can Vet J 2010, 51:1109-1111.
• [31]Jain RK: Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005, 307:58-62.
• [32]Lambert E, Dassé E, Haye B, Petitfrère E: TIMPs as multifacial proteins. Critical Rev Oncol/Hematol 2004, 49:187-198.
• [33]Ree AH, Florenes VA, Berg JP, Maelandsmo GM, Nesland JM, Fodstad O: High levels of messenger RNAs for tissue inhibitors of metalloproteinases (TIMP-1 and TIMP-2) of primary breast carcinomas are associated with development of distant metastases. Clin Cancer Res 1997, 3:1623-1628.
• [34]Gonzalez LO, Junquera S, Del Casar JM, González L, Marín L, González-Reyes S, Andicoechea A, González-Fernández R, González JM, Pérez-Fernández R, Vizoso FJ: Immunohistochemical study of matrix metalloproteinases and their inhibitors in pure and mixed invasive and in situ ductal carcinomas of the breast. Human Pathol 2010, 41:980-989.
• [35]Santos A, Lopes C, Frias C, Amorim I, Vicente C, Gärtner F, Matos A: Immunohistochemical evaluation of MMP-2 and TIMP-2 in canine mammary tumours: a survival study. Vet Journal 2011a, 190:396-402.
• [36]Matos AJF, Faustino AMR, Lopes C, Rutteman GR, Gärtner F: Detection of lymph node micrometastases in canine malignant mammary tumours with the use of cytokeratin immunostaining. Vet Record 2006, 158:626-629.
• [37]Elston CW, Ellis IO: Assessment of histological grade. In Rosen’s Breast Pathology. 1st edition. Edited by Rosen PP. Philadelphia: Lippincott-Raven Publ; 1998:365-382.
• [38]Santos AAF, Oliveira JT, Lopes CCC, Amorim IF, Vicente CMFB, Gärtner MFMR, Matos AJF: Immunohistochemical expression of vascular endothelial growth factor in canine mammary tumours. J Comp Pathol 2010, 143:268-275.
• [39]Santos A, Lopes C, Marques RM, Amorim I, Ribeiro J, Frias C, Vicente C, Gärtner F, Matos A: Immunohistochemical analysis of urokinase plasminogen activator and its prognostic value in canine mammary tumours. Vet Journal 2011b, 189:43-48.
• [40]Klein M, Kleinbaum DG: Kaplan-Meier survival curves and the Log-rank test. In Survival Analysis – A Self Learning Text. 2nd edition. Edited by Gail M, Krickeberg K, Samet J, Tsiatis A, Wong W. New York: Springer Science + Business Media LLC; 2005:45-82.